10-Q: Pro-Dex Q1 Revenue Jumps 24%, Net Income Doubles

Pro-Dex, Inc. reported a significant increase in net sales and net income for the first quarter of fiscal 2026, driven by strong orthopedic medical device sales and an unrealized gain on investments.

Summary

• Net sales increased 24% to $18.53 million for the three months ended September 30, 2025, compared to $14.89 million in the prior year period.
• Net income more than doubled to $4.68 million ($1.43 basic EPS) in Q1 FY26, up from $2.47 million ($0.76 basic EPS) in Q1 FY25.
• Gross profit increased 4% to $5.37 million, but gross margin decreased from 35% to 29% due to higher costs, including tariffs.
• Operating income increased 3% to $3.11 million.
• Other income significantly increased to $3.11 million, primarily driven by a $3.30 million unrealized gain on investments.
• Orthopedic medical device sales surged 65% to $11.05 million, primarily due to the launch of a next-generation handpiece for the largest customer.
• Repair revenue decreased 25% to $3.83 million, possibly indicating a shift towards new handpiece replacements over legacy repairs.
• Backlog stands at approximately $46.8 million as of September 30, 2025, with $43.6 million scheduled for delivery during the remainder of fiscal 2026.
• Subsequent to the quarter end, in October 2025, the company received $8.9 million in cash from the acquisition of Monogram Technologies, Inc. by Zimmer Biomet, expecting a realized gain of $6.8 million in Q2 FY26.
• Working capital increased to $37.1 million as of September 30, 2025, from $27.2 million at September 30, 2024.

Sentiment

Score: 8

Explanation: The company delivered strong financial results with significant revenue and net income growth, boosted by investment gains and a major product launch. The subsequent cash infusion from the Monogram acquisition further strengthens its financial position. Positive outlook on customer contracts and new product releases are encouraging. However, the decline in gross margin and high customer concentration are areas to monitor.

Positives

• Net sales increased by 24% to $18.53 million for the three months ended September 30, 2025.
• Net income more than doubled to $4.68 million, up from $2.47 million in the prior year period.
• Basic net income per share increased significantly to $1.43 from $0.76.
• Orthopedic medical device sales grew 65% to $11.05 million, driven by the launch of a next-generation handpiece.
• Total medical device revenue increased 45% to $14.38 million.
• Reported a significant unrealized gain on investments of $3.30 million.
• Received $8.9 million in cash in October 2025 from the Monogram acquisition, with an expected realized gain of $6.8 million in Q2 FY26.
• Strong backlog of $46.8 million, with $43.6 million scheduled for delivery in the remainder of fiscal 2026.
• Working capital increased to $37.1 million as of September 30, 2025.
• Negotiations are underway with the largest customer to extend the contract through calendar 2028, with purchase orders already placed through calendar 2026.
• The Helios driver for CMF applications, featuring adaptive torque-limiting software, is expected to be released for production in Q2 FY26.
• Additional manufacturing capacity from the Franklin Property is operational and supports expected continued growth.

Negatives

• Gross margin decreased by six percentage points, from 35% to 29%, primarily due to higher costs, including tariffs, which have not been fully passed on to customers.
• Product costs increased 33%, which is higher than the 24% revenue increase, partly due to product mix and negative fluctuations in repair service revenue margin.
• Repair revenue decreased by $1.3 million, or 25%, for the three months ended September 30, 2025.
• Under-absorption of manufacturing costs increased to $619,000 from $325,000 in the prior year period.
• Thoracic sales decreased by $515,000, or 51%, for the three months ended September 30, 2025.
• Interest expense increased to $200,000 from $152,000.
• The company is pursuing negotiations to acquire an existing supplier, and if unsuccessful, will be obligated to reimburse the supplier for legal fees up to $62,500.

Risks

• Ability to continue developing new products and increasing sales in markets characterized by rapid technological evolution.
• Consolidation within the target marketplace and among competitors.
• Employee turnover.
• Competition from larger, better capitalized competitors.
• Ability to realize returns on opportunities.
• Economic, competitive, governmental, and technological factors could impact the ability to achieve goals.
• No guarantee or assurance as to the amount of revenue, if any, that may ultimately be recognized from the exclusive right to develop, engineer, manufacture, and supply certain products for Monogram (now Zimmer Biomet).
• No guarantee that existing or new customers will purchase the new Helios driver.
• Variability in new order bookings due to reasons including the timing of major new product launches and customer planned inventory builds.
• No assurance that the company will remain in compliance with all debt covenants for the duration of the term of the Loans.
• Artificial intelligence (AI) may generate incorrect information that is used incorrectly and may lead to an adverse effect on the business, as seen with an erroneous press release in August 2025.
• Confusion may be created by other entities (e.g., Polkadex) trading under the same 'PDEX' symbol, potentially leading to misconstrued alerts or misdirected trades.
• Inherent limitations on the effectiveness of internal controls over financial reporting, which may not prevent or detect misstatements.
• Uncertainty regarding ultimate liability or materiality of legal proceedings.

Future Outlook

The company expects revenue growth in the future, though it may not be a consistent trajectory but rather periods of incremental growth. The Helios driver for CMF applications is anticipated to be released for production in the second quarter of fiscal year 2026, which is expected to increase sustaining and other engineering expenses. The company is evaluating the impact of the 'One Big Beautiful Bill Act of 2025' on its financial statements for fiscal year 2026 but does not expect a material change. Management believes existing cash, cash equivalents, and accounts receivable, along with expected cash flow from operations and the $8.9 million from the Monogram acquisition, will provide sufficient funds for at least the next 12 months. However, debt and/or equity capital may be required to fund working capital needs and capital equipment, with an available balance of $8.8 million on the revolving loan with UMB for additional capital.

Management Comments

• "We continue to focus a significant percentage of our time and resources on providing outstanding products and service to our valued principal customers."
• "Currently, we are in negotiations with our largest customer to extend the contract through calendar 2028. While we are still negotiating some of the specific commercial terms, we have no reason to believe that the contract amendment will not be executed and further, the customer has placed purchase orders to us through the end of calendar 2026."
• "Our patented adaptive torque-limiting software has been very well received in the CMF and thoracic markets."
• "Our latest Pro-Dex branded product, the Helios driver for CMF applications, featuring our adaptive torque-limiting software, is expected to be released for production in the second quarter of this fiscal year."
• "We began operations in the new facility during the fourth quarter of fiscal 2023 and believe that the additional capacity will allow for our continued expected growth."
• "While we expect revenue growth in the future, it may not be a consistent trajectory but rather periods of incremental growth that current expenditures are helping to create."
• "We believe that we are in compliance with all of our debt covenants as of September 30, 2025."
• "We currently believe that our existing cash and cash equivalent balances together with our accounts receivable balances will provide us sufficient funds to satisfy our cash requirements as our business is currently conducted for at least the next 12 months."
• "We are focused on preserving our cash balances by monitoring expenses, identifying cost savings, and investing only in those development programs and products that we believe will most likely contribute to our profitability."

Industry Context

The company operates in the dynamic medical device industry, specializing in surgical drivers and shavers for orthopedic, thoracic, and maxocranial facial markets. The strong growth in orthopedic sales, driven by a new product launch, highlights the importance of innovation and product refresh cycles in this sector. The acquisition of Monogram Technologies by Zimmer Biomet, a larger player, reflects ongoing consolidation trends within the medical device industry. Pro-Dex's continued exclusive development rights post-acquisition could be a strategic advantage, potentially leveraging Zimmer Biomet's resources for product commercialization. The company's emphasis on patented adaptive torque-limiting software and proprietary sealing solutions indicates a strategy focused on technological differentiation in a competitive environment.

Comparison to Industry Standards

• The filing does not provide specific global benchmarks or comparable companies/projects with detailed results for direct comparison.
• The company notes 'competition from larger, better capitalized competitors' as a general risk, implying a competitive landscape without naming specific rivals.
• The gross margin of 29% (down from 35%) could be assessed against industry averages for specialized medical device manufacturers, but no such data is provided in the filing for a direct comparison.
• The high customer concentration, with Customer 1 accounting for 78% of sales, is a notable characteristic that could be compared to industry diversification standards, but no specific comparison is made within the filing.

Management Changes

Corporate Governance

Legal Proceedings

• The company may be involved from time to time in legal proceedings arising either in the ordinary course of business or incidental to business, with no certainty that liability will not be material or adverse.
• In August 2025, a law firm posted an erroneous press release inviting shareholders to request an investigation into Pro-Dex, attributing stale information to a stock price decline. The firm quickly removed these items before the company initiated a request.

Related Party Transactions

• Investment in common stock of Air T, Inc. totaling $1.1 million at September 30, 2025. Two Board members also serve on Air T, Inc.'s board, and both, individually or through affiliates, own an equity interest. The company's Chairman also serves as CEO and Chairman of Air T, Inc., and another Board member is Chief of Staff at Air T, Inc. These purchases were approved by three non-affiliated Board members.
• Many securities holdings include stocks of public companies that Investment Committee members (Messrs. Swenson or Cabillot) may own from time to time either individually or through investment funds they manage, or other companies whose boards they sit on.

Stakeholder Impact

• Shareholders: Positive impact from increased net income, EPS, and investment gains. Potential for future growth from new products and customer contract extensions. Risks include gross margin compression and potential confusion from similar stock symbols.
• Employees: Positive impact from the ESPP amendment offering a more favorable discount. Share-based compensation plans provide incentives. Potential for increased demand and supplier acquisition could lead to job security and growth opportunities.
• Customers: The largest customer is benefiting from the next-generation handpiece, and ongoing contract extension negotiations indicate a strong, continuing relationship. New product developments like the Helios driver offer potential new solutions.
• Suppliers: Potential acquisition of an existing supplier could impact the supplier landscape and relationships.
• Creditors (UMB Bank): The company believes it is in compliance with all debt covenants. Strong liquidity position and the recent cash inflow from the Monogram acquisition reduce credit risk.

Next Steps

• Continue negotiations with the largest customer to extend the supply agreement through calendar 2028.
• Pursue negotiations with an existing supplier to acquire their business to meet expected increased demand for the next-generation handpiece.
• Release the Helios driver for CMF applications for production in the second quarter of fiscal year 2026.
• Evaluate the impact of the 'One Big Beautiful Bill Act of 2025' on financial statements for the fiscal year ended June 30, 2026.
• Monitor expenses and identify cost savings to preserve cash balances.
• Invest in development programs and products that are most likely to contribute to profitability.

Key Dates

Recommendation

The company's Q1 FY26 results demonstrate exceptional financial performance, with a 24% increase in net sales and a doubling of net income, significantly bolstered by a $3.3 million unrealized investment gain. The subsequent $8.9 million cash proceeds from the Monogram acquisition, with an expected $6.8 million realized gain in Q2, further strengthens the balance sheet and liquidity. Strategic initiatives, including the successful launch of a next-generation orthopedic handpiece and ongoing negotiations for a major customer contract extension through 2028, indicate robust future growth potential. While gross margin compression and customer concentration are noted, the overall trajectory, strong backlog, and proactive management of capital resources present a compelling investment case for a seasoned investor.

Keywords

Medical devices, Surgical drivers, Orthopedic, CMF, Thoracic, Adaptive torque-limiting software, SEC filing, 10-Q, Financial results, Net sales, Net income, Investments, Monogram Technologies, Zimmer Biomet, Backlog, Manufacturing, Supply chain, Corporate governance, Risk management, PDEX